The global epigenomic market was valued US$ 5.28 Bn in 2017 and is expected to reach US$ 16.3 Bn by 2026

Publish Date: Mar 2021

Category: Healthcare, Pharmaceuticals & Medical Devices

Publisher: Maximize Market Research

Status: Publish

The global epigenomic market was valued US$ 5.28 Bn in 2017 and is expected to reach US$ 16.3 Bn by 2026, at a CAGR of 15.13 % during a forecast period.

Growing applications in personalized medicine & targeted therapy in oncology and the use of epigenetics in non-oncology applications is a growth opportunity for the epigenetics market.

Increase in the prevalence of cancer & other chronic diseases, a rise in the aging population, and a decrease in the sequencing costs & time is driving the growth of the market. Growth in funding for research & development, need for better cancer therapies, development in personalized medicine, and the increasing importance of epigenetic technology is also boosting the market growth. The high cost of instruments is limiting the growth of the market. Some challenges of the market are concerns regarding the quality of antibodies, and a lack of trained professionals.

Reagents segment include antibodies, buffers, histones, and magnetic beads. Reagents are used in the analysis of epigenetic changes and it is contributed the maximum shares to the epigenetics market owing to the sales volume of reagents is high in comparison to other equipment. The sales volume of reagents is high due to their increased affordability & ease of storage in less space. Oncology deals with tumors and cancers.

Rise in the number of collaborations between the large pharmaceutical companies to get into innovation & produce technologically advanced and effective products & service in North-America is leading the global epigenomic market. An Asia-pacific epigenomic market is estimated to grow rapidly, owing to the high incidence of cancer, a large occurrence of target diseases, the rise in healthcare expenditure, the increase in investments & funds, and various emerging applications.

The key player operating in the global epigenomic market are Abbott Laboratories, Affymetrix, Agilent Technologies, Astellas Pharmaceuticals, Bayer Ag, Bio Vision, Celgene Corp., Epigenomics Ag, Epigentek, Glaxosmithkline, Illumina Inc., Johnson & Johnson, Laboratory Corp. Of America Holdings, Merck Sharp & Dohme, Naturewise Biotech & Medicals Corp., Novartis Pharma Ag, Orchid Chemicals & Pharmaceuticals Limited, Tbg Diagnostics Limited, Rubicon Genomics, and Roche Holding Ag.

The Scope of Global Epigenomic Market:

Global Epigenomic Market, by Product:


  Instruments and Consumables



  Bioinformatics Tools

Global Epigenomic Market, by Application:


  Metabolic Diseases

  Developmental Biology


  Cardiovascular Diseases

  Other application

Global Epigenomic Market, by Technology:

  DNA Methylation

  Histone Modifications

  Other Technologies

Global Epigenomic Market, by End-User:

  Academic & Research Institutes

  Pharmaceutical & Biotechnology Companies

  Contract Research Organizations

Global Epigenomic Market, by Region:

  North America



  South America

  Middle East & Africa

Key Player Operating In the Global Epigenomic Market:

  Abbott Laboratories


  Agilent Technologies

  Astellas Pharmaceuticals

  Bayer Ag

  Bio Vision

  Celgene Corp.

  Epigenomics Ag



  Illumina Inc.

  Johnson & Johnson

  Laboratory Corp. Of America Holdings

  Merck Sharp & Dohme

  Naturewise Biotech & Medicals Corp.

  Novartis Pharma Ag

  Orchid Chemicals & Pharmaceuticals Limited

  Tbg Diagnostics Limited

  Rubicon Genomics

  Roche Holding Ag

Table of Contents
Ask For Analyst

Choose License Type